Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Modern controlled human malaria infection (CHMI) clinical trials have almost entirely focussed on Plasmodium falciparum, providing a highly informative means to investigate host-pathogen interactions as well as assess potential new prophylactic and therapeutic interventions. However, in recent years, there has been renewed interest in Plasmodium vivax, with CHMI models developed by groups in Colombia, the USA, and Australia. This review summarizes the published experiences, and examines the advantages and disadvantages of the different models that initiate infection either by mosquito bite or using a blood-stage inoculum. As for P. falciparum, CHMI studies with P. vivax will provide a platform for early proof-of-concept testing of drugs and vaccines, accelerating the development of novel interventions.

Original publication

DOI

10.1016/j.pt.2016.11.001

Type

Journal article

Journal

Trends in parasitology

Publication Date

02/2017

Volume

33

Pages

141 - 150

Addresses

The Jenner Institute Laboratories, Old Road Campus Research Building, University of Oxford, Oxford, OX3 7DQ, UK; The Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, OX3 7LE, UK. Electronic address: ruth.payne@ndm.ox.ac.uk.

Keywords

Animals, Humans, Plasmodium falciparum, Plasmodium vivax, Malaria, Falciparum, Malaria, Vivax, Models, Biological, Host-Pathogen Interactions